Farrell Barbara, Tsang Corey, Raman-Wilms Lalitha, Irving Hannah, Conklin James, Pottie Kevin
Bruyère Research Institute, Ottawa, Canada; Department of Family Medicine, University of Ottawa, Ottawa, Canada; School of Pharmacy, University of Waterloo, Waterloo, Canada.
Bruyère Research Institute, Ottawa, Canada; School of Pharmacy, University of Waterloo, Waterloo, Canada.
PLoS One. 2015 Apr 7;10(4):e0122246. doi: 10.1371/journal.pone.0122246. eCollection 2015.
Polypharmacy and inappropriate medication use among older adults contribute to adverse drug reactions, falls, cognitive impairment, noncompliance, hospitalization and mortality. While deprescribing - tapering, reducing or stopping a medication - is feasible and relatively safe, clinicians find it difficult to carry out. Deprescribing guidelines would facilitate this process. The aim of this paper is to identify and prioritize medication classes where evidence-based deprescribing guidelines would be of benefit to clinicians. A modified Delphi approach included a literature review to identify potentially inappropriate medications for the elderly, an expert panel to develop survey content and three survey rounds to seek consensus on priorities. Panel participants included three pharmacists, two family physicians and one social scientist. Sixty-five Canadian geriatrics experts (36 pharmacists, 19 physicians and 10 nurse practitioners) participated in the survey. Twenty-nine drugs/drug classes were included in the first survey with 14 reaching the required (≥ 70%) level of consensus, and 2 new drug classes added from qualitative comments. Fifty-three participants completed round two, and 47 participants completed round three. The final five priorities were benzodiazepines, atypical antipsychotics, statins, tricyclic antidepressants, and proton pump inhibitors; nine other drug classes were also identified as being in need of evidence-based deprescribing guidelines. The Delphi consensus process identified five priority drug classes for which expert clinicians felt guidance is needed for deprescribing. The classes of drugs that emerged strongly from the rankings dealt with mental health, cardiovascular, gastroenterological, and neurological conditions. The results suggest that deprescribing and overtreatment occurs through the full spectrum of primary care, and that evidence-based deprescribing guidelines are a priority in the care of the elderly.
老年人的多重用药和不适当用药会导致药物不良反应、跌倒、认知障碍、治疗依从性差、住院和死亡。虽然减药——逐渐减少或停用药物——是可行且相对安全的,但临床医生发现很难实施。减药指南将有助于这一过程。本文的目的是确定哪些药物类别需要基于证据的减药指南,并对其进行优先级排序,以便为临床医生提供帮助。一种改良的德尔菲法包括进行文献综述以确定老年人潜在的不适当用药,组建一个专家小组来制定调查内容,并进行三轮调查以就优先级达成共识。专家小组成员包括三名药剂师、两名家庭医生和一名社会科学家。65名加拿大老年医学专家(36名药剂师、19名医生和10名执业护士)参与了此次调查。第一轮调查纳入了29种药物/药物类别,其中14种达到了所需的(≥70%)共识水平,并根据定性评论新增了2种药物类别。第二轮有53名参与者完成,第三轮有47名参与者完成。最终确定的五个优先药物类别为苯二氮䓬类药物、非典型抗精神病药物、他汀类药物、三环类抗抑郁药和质子泵抑制剂;另外还有九种药物类别也被确定需要基于证据的减药指南。德尔菲共识过程确定了五个优先药物类别,专家临床医生认为在这些类别进行减药时需要指导。在排名中突出出现的药物类别涉及心理健康、心血管、胃肠和神经疾病。结果表明,在整个初级保健过程中都存在减药和过度治疗的情况,并且基于证据的减药指南是老年护理中的一个优先事项。